BAB VI KESIMPULAN DAN SARAN
6.2 Saran
1. Perlunya penelitian lebih lanjut dengan sampel lebih besar dan desain penelitian kohort ataupun uji survival untuk mendapatkan hubungan antara PCT, skor CURB-65 dengan mortalitas penderita PK.
2. Penelitian lebih lanjut perlu mengikutsertakan pasien dengan daya tahan menurun (immunocompromised) sehingga dapat membantu memutuskan pemberian antibiotik pada populasi tersebut.
3. Dibutuhkan studi lebih lanjut bagaimana hubungan PCT derajat bakteremia (bacterial load) dan bagaimana kadar PCT jika terdapat koinfeksi bakteri dan virus.
34
DAFTAR PUSTAKA
1. Summary Executive. Pola Penyakit Penyebab Kematian di Indonesia. Survei Kesehatan Rumah Tangga (SKRT). 2001: 2.
2. Dahlan Z. Pandangan Baru Pneumonia Atipik dan Terapinya. Cermin Dunia Kedokteran. 2000;128: 6.
3. De Frances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. National Health Statistic Reports. 2008;5: 1 – 20.
4. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et.al. Risk Prediction with Procalcitonin and Clinical Rules in Community Acqiured Pneumonia. Ann Emerg Med. 2008; 52(1): 48- 58.
5. Mira JP, Max A, Burgel PR. The Role of Biomarker in Community Acquired Pneumonia: Prediciting Mortality and Response to Adjunctive Therapy. Critical Care. 2008;12(Suppl 6): 1-7.
6. Singanayagam A, Chalmers JD, Hill AT. Severity Assesment in Community Acquired Pneumonia: a review. QJ med. 2009; 102: 379-88. 7. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et.al.
British Thoracic Society Guidelines For The Management of Community Acquired Pneumonia in Adults: update 2009. Thorax. 2009; 64(suppl II): 1
– 55.
8. Mandell LA, Wunderik RG, Arzueto A, Bartlett JG, Campbell GD, Dean NC, et.al. Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on The Management of Community Acquired Pneumonia in Adults. CID. 2007; 44: 27- 72.
9. Capelastegui A, Espana PP, Quintana JM, Arcitio I, Gorondo I, Egurolla M, et.al. Validation of Predictive Rule for the management of Community Acquired Pneumonia. Eur Respir J. 2006; 27: 151-57.
10. Summah H, Qu JM. Biomarkers: A Definite Plus in Pneumonia. Mediator of Inflamation. 2009: 1-9.
34
11.
Cairns C. Procalcitonin. Department of Anaesthetics. University of Kwazulu-Natal. 2010: 3 – 24.
12. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et.al. Diagnostic and Prognostic Accuracy of Clinical and Laboratory Parameters in Community Acquired Pneumonia. BMC Infectious Diseases. 2007; 7: 1- 10.
13. Christ-Crain M, Stolz D, Bingisser R, Mueller C, Mledinger D, Huber P, et.al. Procalcitonin Guidance of Antibiotics Therapy in Community Acquired Pneumonia. Am J Respir Crit Care Med. 2006; 174: 84 -93. 14. Christ-Crain M, Opal SM. Clinical Review: The Role of Biomarkers in the
Diagnosis and Management of Community Acquired Pneumonia. Critical care. 2010; 14: 1- 11.
15. Kruger S, Ewig S, Marne R, Papassotisiou J, Richter K, Von Baum H, et.al. Procalcitonin Predicts Patient at Low Risk of Death from Community Acquired Pneumonia Across all CRB-65 Classes. Eur Respir J. 2008; 31: 349-55.
16. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble
WT, et.al. Pneumonia: Still the Oldman’s Friend?. Arch Intern Med. 2003;
163: 317-23.
17. Hendlund J, Hansson LO. Procalcitonin and C-Reactive Protein Levels in Community Acquired Pneumonia: Correlation With Etiology and Prognosis. Infection. 2000; 28: 68 – 72.
18. Masia M, Gutierrez F, Shum C, Padilla, Sergio, et.al. Usefulness of Procalcitonin Level in Community Acquired Pneumonia According to Patients Outcome Research Team Pneumonia Severity Index. Chest. 2005; 128: 23-29.
19. Kosanke R, Beier W, Lipecky R, Meisner M. Clinical Benefits of Procalcitonin. Tannafos. 2008; 7:14 – 18.
20. Chastre J, Luyt CE, Trouillet JL, Combes A. New Diagnostic and Prognostic Markers of Ventilator Associated Pneumonia . Current Opnion in Critical Care. 2006; 12: 446-51.
21. Maier M, Wutzler S, Lehnert M, Szermutzky, Hendrik W, Bingold T, et.al. Serum Procalcitonin Level in Patients with Multiple Injuries Including Viseral Trauma. Journals of Trauma. 2009; 66: 243-49.
22. Tseng JS, Chan MC, Hsu JY, Kuo BIT, Wu CL. Procalcitonin is a Valuable Prognostic Markers in ARDS caused by Community Acquired Pneumonia. Respirology. 2008;13: 505-9.
23. Jung DY, Park JB, Lee EN, Lee HT, Joh JW, Kwon CH, et. al. Combined use of Myeloid-related protein 8/14 and Procalcitonin as diagnostic markers for acute allograft rejection in kidney transplantation recipients. Transplant Immunology. 2008; 18: 338-43.
24. Gilbert DN. Use of Plasma Procalcitonin Levels as an Adjunct to Clinical Microbiology. Journal of Clinical Microbiology. July 2010: 2325-29. 25. Aabenhus R, Jensen JUS. Procalcitonin-Guided antibiotik treatment of
respiratory tract infection in primary care setting: are we there yet?. Prim Care Respir J. 2011; 20: 305-19
26. Irwin AD, Carrol ED. Procalcitonin. Arch Dis Child Educ Pract Ed . 2011: 228-33.
27. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotik decisions: past, present and future. BMC 2011;9 :107.
28. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infection- hope for hype ?. SWISS MED WKLY 2009; 139: 318-26.
29. Simon L, Gauvin F, Amre DK, Saint-louis P, Lacroix J. Serum Procalcitonin and C- Reactive Protein Levels as Markers of Bakteri Infection : a systematic review and metaanalysis. Clin Infect Dis 2004; 39: 206- 17.
30. Bont J, Hak E, Hoes AW, Macfarlane JT, Verheij TJM. Predicting Death in Elderly Patients with Community Acquired Pneumonia: A Prospective Validation Study Reevaluating the CRB-65 Severity Assesment Tool. Arch Intern Med. 2008; 168: 1465-68.
31. Querol-Ribelles JM, Tenias JM, Grav E, Querol-Borras JM, Climent JL, Gomez E, et.al. Plasma d-dimer levels correlate with outcomes in patient with Community Acquired Pneumonia. Chest. 2004; 126: 1087-92.
32. Rumende CM. Procalcitonin dan Lipopolysaccharide-Binding Protein Sebagai Prediktor dan Petanda Prognostik Ventilator Associated Pneumonia pada Pasien HCU/ICU RSCM tahun 2006-2007. Diunduh dari
: www.majalah-farmacia.com/rubrik/one-news
33. Dahlan Z. Pneumonia. Dalam: Sudoyo AW, Setyohadi B, Alwi I, Simadibrata M, Setiati S (editors). Buku Ajar Ilmu Penyakit Dalam (Jilid III): Interna Publishing; 2009:2196-2206.
34. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, et.al. Severe Community Acquired Pneumonia As Cause Of Severe Sepsis: Data from PROWESS study. Crit Care Med, 2005; 33(5): 952-61. 35. American College of Chest Physicians/Society of Critical Care Medicine
Consensus Conference: Definitions for Sepsis and Organ Failure and Guidelines for The Use of InnovativeTherapies in Sepsis. Critical Care Medicine, 1992. Vol 20 no 6.
36. Kasper, Braunwald, Fauci, Hauser, Longo, Jameson(Editors). Sepsis and Septic Shock. Harrison’s Manual Of Medicine, 18 th Edition, Mc Graw Hill, 2005:49-53
37. Dremsizov T, Clermont G, Kellum JA, Kallassian KG, Fine MJ, Angus DC. Severe Sepsis in CAP: When Does It Happen, and do SIRS Help Predict Course?. Chest, 2006;129:968-78.
38. Nayak SB, Sakhamuri MS, Raghunanan B, Allison A, Uppalapati K, Patcha K. The role of serum markers in assessing the severity and outcome of community acquired pneumonia in Trinidadian population. Journal of Public Health and Epidemiology, 2010: 20-24.
39. Purba DB. Kadar Procalcitonin Sebagai Marker dan Hubungannya dengan Derajat keparahan Sepsis (Tesis). Departemen Ilmu Penyakit Dalam, Universitas Sumatera Utara, Medan; 2010: 32.
40. Carol P, Kathryn JG. Alteration of Urinary System. In:Essentials of Pathophysiology. Lippincott Williams & Wilkins, 2003:411.
41. Rosner MH, Okusa MD. Patogenesis and etiology of postischemic acute tubular necrosis. UpToDate 2009. Available from : http://
www.uptodate.com
42. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a Marker for the detection of bacteremia and Sepsis in Emergency department. Am J Clin Patho, 2011;135: 182-89.
